Cysteamine Pantetheine Disulfide

Cysteamine Pantetheine Disulfide is a compound that potentially influences several biological processes, largely through its breakdown products and their interactions within the body. Here's a look at how it works based on available evidence:

Disulfide Modifications and Metabolism:
According to the 2005 study in "Free Radical Research," disulfide modifications play a significant role in signal transmission. Cysteamine pantetheine disulfide might participate in these modifications, affecting cell signaling pathways through interactions involving S-glutathionyl and S-cysteaminyl disulfides. This suggests a potential influence on cellular communication and redox status.

Pantetheinase Inhibition:
The 1994 research published in "European Journal of Biochemistry" discusses how disulfides can inhibit pantetheinase, an enzyme that breaks down pantetheine into pantothenic acid and cysteamine. By interfering with this process, cysteamine pantetheine disulfide could alter levels of these metabolites, potentially impacting coenzyme A biosynthesis and related metabolic pathways.

Vanin-1 and Oxidative Stress:
The study from "Current Medicinal Chemistry" in 2015 indicates that Vanin-1, an enzyme involved in pantothenic acid metabolism, could be influenced by the compound or its metabolites during oxidative stress conditions. This enzyme's activity is linked to the regulation of glutathione, a critical antioxidant in cellular protection against oxidative damage.

Lipomodulation and Hormonal Effects:
The 1987 "Atherosclerosis" and 1985 "Endocrinology" studies suggest that cysteamine, a breakdown product of pantethine, is involved in lipid metabolism and hormonal depletion, such as somatostatin and prolactin. This indicates potential effects on lipid profiles and endocrine function through metabolic and signaling pathways.

Overall, cysteamine pantetheine disulfide may work by modulating enzymatic activity and redox states, potentially influencing metabolic, oxidative, and signaling pathways. However, detailed studies specific to its complete mechanism are limited.

Disclaimer: This summary is for informational purposes and is not a substitute for professional medical advice. Always consult a healthcare professional for medical concerns.

Cysteamine Pantetheine Disulfide is being explored for several clinical applications based on its biochemical activities and effects observed in various trials and research studies.

1. Inflammatory and Oxidative Stress Conditions:

   • The research outlined in "Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions" suggests potential roles in modulating oxidative stress responses and inflammation. Specifically, Vanin-1, an enzyme influencing oxidative stress by modulating glutathione levels, may be affected by this compound. This indicates possible benefits in conditions characterized by oxidative stress.

2. Neurological Disorders:

   • Cysteamine-Pantetheine Disulfide was studied for its potential effects on neurological disorders, such as Leigh Syndrome Spectrum (LSS) and MELAS. Although the trial targeting TBI was withdrawn, the completed study (NCT06644534) in MELAS patients suggests ongoing interest in its application for mitochondrial and neurological conditions due to its metabolic influence.

3. Infectious Diseases:

   • A Phase 2 study (NCT05212662) was planned to investigate the compound's use in mild to moderate COVID-19, though it was ultimately withdrawn. This highlights the potential interest in its application for modulating immune responses during infections.

4. Lipomodulation and Endocrinology:

   • Historical studies have shown that pantethine, related to cysteamine, impacts lipid metabolism and endocrine functions. Research such as "Pantethine lipomodulation: evidence for cysteamine mediation in vitro and in vivo" suggests benefits in managing lipid profiles, possibly reducing cardiovascular risk.

These diverse clinical explorations reflect the compound's potential versatility, although more robust clinical data is needed to establish definitive applications.

Disclaimer: This information is based on a summary of available research and clinical trials. For personalized medical advice, please consult a healthcare professional.

Safety Profile of Cysteamine Pantetheine Disulfide

Known Side Effects

Based on the available evidence, specific side effects of cysteamine pantetheine disulfide are not well-documented. Historical studies concerning its related compounds indicate potential metabolic and hormonal impacts, such as depletion of somatostatin and prolactin in rats. However, the direct relevance to current clinical applications is unclear.

Contraindications

No explicit contraindications are detailed in the existing studies for cysteamine pantetheine disulfide. Due to the lack of comprehensive data, it is prudent to approach use with caution, especially in populations with preexisting metabolic or hormonal disorders.

Drug Interactions

The evidence does not provide specific information about drug interactions involving cysteamine pantetheine disulfide. Given its metabolic role, interactions with medications affecting similar pathways (e.g., disulfide-containing drugs) are possible.

Populations to Avoid Use

No studies explicitly delineate populations that should avoid this compound. However, the sparse evidence suggests caution in using it among patients with oxidative stress conditions and liver disorders, given its metabolic influence observed in these contexts.

Evidence Limitations

Overall, the current data on safety, side effects, contraindications, and interactions of cysteamine pantetheine disulfide is limited. Most studies focus on related biochemical pathways or provide indirect evidence. Clinical trials related to this compound have been withdrawn or are yet to begin, indicating a need for further research before definitive safety guidelines can be established.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Consult a healthcare provider for guidance tailored to personal health needs.

Research on Cysteamine Pantetheine Disulfide (TTI-0102) covers various biochemical and therapeutic aspects. Below is a synthesis of key studies and trials:

Biochemical and Mechanistic Studies:

1. Vanin-1's Role in Oxidative Stress: A study from 2015 in "Current Medicinal Chemistry" explored how Vanin-1 and its catalytic products impact the liver during normal and oxidative stress. The findings suggest that alterations in these biochemical processes may influence cellular responses and disease states (PMID: 26549544).

2. Metabolism Tracking: A 2013 study in "Analytical Chemistry" used an innovative technique to track the metabolism of related compounds, including cystamine and pantethine. This research provides insight into how these compounds are processed in the body and influences drug development (PMID: 24215585).

3. Disulfide Modifications in Cell Signaling: The 2005 paper in "Free Radical Research" focused on the significance of disulfide modifications, including S-cysteaminyl, in cellular signaling, indicating potential pathways for therapeutic targeting (PMID: 16036322).

4. Pantetheinase Inhibition: A 1994 study in the "European Journal of Biochemistry" investigated the inhibition of pantetheinase by disulfides, which may influence therapeutic strategies involving enzyme modulation (PMID: 7957261).

5. Cysteamine in Lipid Metabolism: The 1987 research in "Atherosclerosis" examined pantethine's effects on lipid metabolism, proposing cysteamine as a mediator in modulating lipids in vitro and in vivo (PMID: 3689482).

6. Metabolism and Hormone Depletion: The studies from 1985 delved into pantethine's metabolism in cystinosis (PMID: 4056044) and its effects on hormone levels like somatostatin and prolactin in rats, shedding light on its potential systemic impacts (PMID: 2862009).

Clinical Trials:
Cysteamine Pantetheine Disulfide (TTI-0102) has been explored in several clinical trials:

1. COVID-19 Trial (NCT05212662): This Phase 2 trial was withdrawn and aimed to evaluate TTI-0102 in patients with mild to moderate COVID-19.

2. Leigh Syndrome Spectrum Study (NCT06990984): Planned as a Phase 2, dose-ranging study in adults and children, this trial is not yet recruiting, aiming to understand TTI-0102's effects on Leigh Syndrome.

3. MELAS Patients Study (NCT06644534): Completed Phase 2 trial assessed TTI-0102 versus placebo in patients with MELAS, a mitochondrial disorder, providing valuable data on efficacy and safety.

4. TBI Trial for Veterans (NCT04262895): Also withdrawn, this study was designed to evaluate TTI-0102’s potential benefits for veterans with traumatic brain injury in a combined Phase 1/2 trial.

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice.

Currently, there are no specific dosing protocols publicly available for cysteamine pantetheine disulfide based on the studies and clinical trials reviewed. Although some clinical trials involving TTI-0102, a form of cysteamine pantetheine disulfide, have been noted, they either were not completed or are in stages that do not disclose detailed dosing information.

For instance, a Phase 2 trial for cysteamine pantetheine disulfide in patients with Leigh Syndrome Spectrum (NCT06990984) is not yet recruiting, and another related to MELAS (NCT06644534) has been completed but does not publicly report dosing specifics. Other trials, such as those for COVID-19 and traumatic brain injury, were withdrawn.

Therefore, without additional data from completed and published studies or trial results, we cannot provide detailed or reliable dosing instructions for cysteamine pantetheine disulfide at this time.

Disclaimer: This information is intended for educational and informational purposes only. It is not personalized medical advice. For personal medical advice, consult a qualified healthcare professional.

The available literature on cysteamine pantetheine disulfide primarily provides insights into its biochemical interactions and potential therapeutic uses rather than concrete clinical outcomes.

The studies discuss various biochemical properties and effects:

1. Biochemical Effects: Some studies, such as those in "Current Medicinal Chemistry" and "Analytical Chemistry," examine the interaction of cysteamine, pantethine, and disulfide compounds under oxidative stress and in metabolic processes. However, these focus on mechanistic insights rather than direct clinical outcomes.

2. Potential Inflammation Modulation: Evidence from "The Journal of Clinical Investigation" suggests a potential role for similar compounds in altering inflammation, possibly through glutathione modulation. However, cysteamine pantetheine disulfide's specific effects were not detailed.

3. Potential Lipid Modulation: Historical studies, like those in "Atherosclerosis" from 1987, inferred that cysteamine derivatives might influence lipid modulation. The strength and clinical applicability of this outcome remain uncertain due to the age and nature of the study.

4. Hormonal and Neurological Impact: An older study in "Endocrinology" describes how related compounds might impact hormone levels such as somatostatin and prolactin in animal models, but this lacks direct clinical outcome relevance.

5. Clinical Trial Stages: The clinical trials database indicates a small number of trials related to TTI-0102 (the formulation of interest) in conditions like COVID-19 and mitochondrial diseases such as MELAS and Leigh Syndrome. Unfortunately, key trials were withdrawn or not yet recruiting, and no results on measurable outcomes are available.

Overall, while there is interest in the potential biochemical and therapeutic effects of cysteamine pantetheine disulfide, the evidence base for clinical outcomes is sparse and largely indirect at this time. Further research and clinical trials are needed to establish its efficacy and safety in humans.

Disclaimer: This summary is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for medical guidance.